How Pharma CEOs Delegate HR and Organizational Development

Pharmaceutical and biotech companies face distinctive HR and organizational development challenges. The talent market for scientific, regulatory, and commercial expertise is intensely competitive. Organizations can shift rapidly between phases, from discovery to clinical development to commercial launch, each requiring different organizational capabilities. And the stakes of getting culture right in a pharma company are unusually high: a culture that does not support rigorous science or compliance discipline can create patient safety risks, regulatory failures, and career-ending consequences for the CEO.

These pressures lead many pharma CEOs to stay too deeply involved in HR and organizational development. They attend talent reviews for positions several levels below them. They participate in culture workshops that CHRO should be leading. They make individual hiring decisions that their functional leaders should own.

Effective HR delegation requires the pharma CEO to be strategic and disciplined about where their involvement adds unique value, what the CHRO should own independently, and how to build people systems that support the organization’s scientific and commercial mission.

What Makes Pharma HR Delegation Distinctive

Several features of pharmaceutical organizations shape the HR delegation challenge. Scientific talent is highly specialized and mobile. The regulatory environment creates compliance requirements that HR must navigate carefully, from FDA workforce practices to GCP compliance for clinical staff. Commercial launch periods require rapid talent scaling under intense pressure. And mergers, partnerships, and program milestones create organizational transitions that put culture at risk.

These features do not justify CEO involvement in routine HR operations. They do justify CEO investment in strong CHRO leadership, adequate HR infrastructure, and deliberate culture management during the organization’s most significant transitions.

What the CEO Must Own in HR and Organizational Development

Executive team composition. The CEO’s most consequential organizational decision is who sits on the executive team. Selecting, developing, and when necessary, replacing executives is the CEO’s most important people management responsibility. This includes making difficult decisions about executives who are performing adequately but not at the level the organization requires as it grows.

C-suite succession planning. Who could replace the CEO, and who could replace each C-suite member, is a CEO and board governance responsibility. Succession planning at this level requires CEO engagement to identify candidates, develop their capabilities, and ensure the board has adequate information to manage a CEO transition if needed.

Culture during major organizational transitions. Pharma companies go through transformative moments: drug approvals, clinical failures, mergers, major restructurings. During these transitions, culture is at risk. When a company moves from a research organization to a commercial organization after its first approval, the cultural shift required is significant. The CEO must lead this cultural transition, because CHRO cannot do it alone. The CEO’s words, decisions, and behaviors during major transitions send the signals that shape organizational culture.

Diversity and inclusion strategy at the organizational level. The commitment to building a diverse and inclusive organization that can attract talent from the full available pool is a CEO-level priority in a sector where scientific talent diversity is both a moral imperative and a competitive advantage.

What the CHRO Should Own

The CHRO is the right owner for the operational and programmatic layer of HR and organizational development. This includes:

• Talent acquisition programs for all roles below the C-suite
• Compensation and benefits design and administration
• Performance management system design and annual cycle management
• Learning and development programs including scientific training, leadership development, and compliance training
• HR business partner deployment and effectiveness
• Employee relations management
• HR compliance and employment law management
• HRIS management and workforce analytics
• Organizational design support for functional restructuring
• Engagement survey management and action planning
• Talent development programs for high-potential employees

The CEO’s relationship with the CHRO should focus on strategic people priorities, executive team health, and culture during major transitions, not on program management or HR operations.

For the broader pharma delegation framework, see the pharma CEO delegation guide.

Delegating Talent Development Programs

Leadership development, scientific career development, and management training programs are HR functions that should be entirely designed and managed by the CHRO, with the CEO’s involvement limited to two roles: setting strategic priorities and being a participant when a program calls for CEO engagement.

The CEO should communicate the organizational capabilities most important to develop, such as scientific leadership, commercial acumen, or cross-functional collaboration, so that the CHRO can design development programs that are strategically aligned. The CEO should also make themselves available to participate in leadership programs in ways that signal organizational commitment, for example, presenting at a leadership development summit or participating in a mentoring program.

Everything else in talent development, including program design, vendor selection, curriculum development, delivery, and evaluation, belongs to the CHRO and HR team.

Empowering HR Business Partners

HR Business Partners are the connective tissue between the HR function and the business. In a pharma company, HRBPs typically support specific functions such as R&D, clinical, regulatory, commercial, and manufacturing, providing HR expertise directly to functional leaders.

Empowering HRBPs requires that they have genuine authority to provide HR guidance without constantly seeking CHRO or CEO approval. HRBPs should be able to advise on employee relations situations, coach managers on performance management, provide compensation analysis, and support organizational design conversations independently.

The CEO’s role relative to HRBPs is indirect: ensuring that HRBP roles are adequately resourced and positioned, and ensuring that functional leaders take HRBP guidance seriously rather than bypassing HR by going directly to the CEO. When a functional leader brings a people management issue directly to the CEO, the CEO should redirect them to work with their HRBP rather than substituting for HR as the decision-maker.

Building People Accountability Systems for a Science-Driven Organization

Pharma organizations face particular challenges in building accountability systems that work for scientific talent. Scientists and researchers are often motivated by discovery and impact, not by traditional managerial accountability frameworks. Regulatory professionals operate in a compliance-driven environment that requires different accountability structures than commercial roles. And the rapid phase transitions of pharma organizations mean that accountability systems need to be adaptable.

A people accountability system that works in pharma typically includes:

Role-specific performance frameworks. Performance expectations for a clinical scientist, a regulatory affairs professional, and a commercial sales manager are fundamentally different. The CHRO should design performance frameworks that are meaningful for each major talent segment.

Scientific leadership development pathways. Pharma companies need dual career tracks, scientific and managerial, that allow top scientific talent to grow without being forced into management roles. The CHRO owns the design of these pathways; the CEO signals their importance.

Milestone-linked organizational reviews. Major program milestones, such as IND filing, Phase 2 results, or commercial launch planning, are natural moments for organizational capability reviews. The CEO and CHRO should build milestone-triggered organizational reviews into the planning cycle.

Research from McKinsey on pharmaceutical company performance consistently identifies talent and organizational capability as key differentiators between companies that successfully launch drugs and those that do not. Building the HR systems that develop this capability is a strategic CEO priority, even if the CHRO owns the operational execution.

For more on how HR delegation connects to regulatory strategy, see pharma regulatory delegation.

Common Delegation Failures in Pharma HR

CEO involvement in individual hiring below the C-suite. When the CEO participates in hiring decisions for roles several levels below the executive team, they signal that organizational leaders cannot trust their own hiring judgment. This undermines manager capability development and creates bottlenecks that slow talent acquisition in a competitive market.

Culture delegated entirely to HR. Culture is not an HR program. It is the accumulated product of leadership behaviors, organizational decisions, and the values that the CEO models daily. CEOs who treat culture as something the CHRO manages miss their most important organizational development lever.

CHRO without genuine authority. A CHRO who must seek CEO approval for routine HR decisions, whose programs are routinely overridden by functional leaders, or who lacks the organizational credibility to be a genuine executive team peer, cannot build the HR infrastructure a complex pharma organization requires. The CEO must invest in a strong CHRO and genuinely empower the role.

Neglecting culture during major transitions. The scientific rigor that drives pharma success must coexist with a commercial urgency that launches products and generates revenue. Managing this cultural integration during the transition from development to commercial operations is CEO work that cannot be delegated.

Conclusion

Pharma CEOs who effectively delegate HR and organizational development build people systems that can support complex scientific and commercial organizations across multiple organizational phases. The CEO retains ownership of executive team composition, succession planning, and culture during major transitions. The CHRO owns the full operational and programmatic layer of HR, from talent acquisition through performance management to organizational development.

The result is an HR function that operates as a genuine strategic partner, a CHRO who is empowered to build people systems that support mission, and a CEO who is focused on the organizational and people decisions that only they can make.

Related Reading

For further context, explore How Pharma CEOs Delegate Investor Relations and Communications and How Automotive CEOs Delegate Fixed Operations Management.